Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.33 |
| ▸ | CDC25B | P30305 | 6/20 | 0.33 |
| ▸ | GJB2 | P29033 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | ATG7 | O95352 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592031 | 1.00 | PDE2A (0.38) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL18490453 | 1.00 | PDE2A (0.38) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL24539016 | 1.00 | PDE2A (0.38) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL21759078 | 1.00 | PDE2A (0.38) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL21758913 | 0.88 | PDE2A (0.37) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL17106669 | 0.87 | PTPN1 (0.34) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL19412708 | 0.87 | PTPN1 (0.34) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL31063739 | 0.86 | PDE2A (0.37) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL12393373 | 0.86 | PDE2A (0.37) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL27086454 | 0.86 | PDE2A (0.37) | PDE2AHSPA5HTR1APTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3573718-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2018138685-A2 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | PDE2A 100/4885HSPA5 2853/4885HTR1A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.